(Q47745009)

English

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hyun Cheol Chung

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

2

object named as

Narikazu Boku

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Yoon-Koo Kang

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Taroh Satoh

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Min-Hee Ryu

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Yee Chao

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Ken Kato

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Jen-Shi Chen

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Kei Muro

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Won Ki Kang

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Takaki Yoshikawa

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sang Cheul Oh

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Li-Yuan Bai

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Takao Tamura

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Keun-Wook Lee

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Yasuo Hamamoto

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Jong Gwang Kim

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Keisho Chin

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Do-Youn Oh

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Keiko Minashi

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Masahiro Tsuda

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Li-Tzong Chen

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

language of work or name

0 references

publication date

6 October 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

390

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

10111

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

2461-2471

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Disparities in gastric cancer chemotherapy between the East and West

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening of gastric cancer in Asia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Japanese gastric cancer treatment guidelines 2014 (ver. 4).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of gastric cancer in Asia: resource-stratified guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive molecular characterization of gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931827-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)31827-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28993052%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47745009&oldid=1777456132"